Novartis AG (Novartis AG) Additional Paid-In Capital : $0 Mil(As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Additional Paid-In Capital?

Novartis AG Additional Paid-In Capital Historical Data

The historical data trend for Novartis AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Additional Paid-In Capital Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	-	-

Novartis AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Novartis AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Novartis AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.